Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Natural Empagliflozin raw Materials Powder
Product Overview:
Net (Empagliflozin), according to Mr Column by boehringer ingelheim and eli lilly company joint development of a type 2 sodium glucose transporters together (SGLT - 2, sodium - dependentglucosecotransporter2) inhibitors. SGLT-2 inhibitor is a new type of hypoglycemic agent. By inhibiting the expression of SGLT-2, it can reduce the kidney's glucose reabsorption and increase the excretion of glucose in urine, thus reducing the plasma glucose level. Its hypoglycemic effect is independent of β cell function and insulin resistance.
Natural Empagliflozin raw Materials Powder Attributes
CAS:864070-44-0
MF:C23H27ClO7
MW:450.91
EINECS:620-176-8
Specification: 99% min Empagliflozin Powder
Sample:Empagliflozin Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Natural Empagliflozin raw Materials Powder Details
Empagliflozin Powder Usage and Synthesis.
Epalliprazin is indicated for the treatment of adults with diabetes who do not achieve adequate glycemic control with diet combined with exercise to improve glycemic control. It should not be used to treat patients with type 1 diabetes, elevated ketones in the blood or urine (diabetic ketoacidosis), severe kidney damage, end-stage kidney disease, and dialysis.
Uses of Empagliflozin.
Pharmacological action of Empagliflozin.
Under physiological environment, the kidney filters and reabsorbs glucose into the circulatory system to maintain the blood glucose balance in the body, while glucose enters the blood through the renal tubule lumen with the cooperation of glucose cotransport protein. SGLT2, as a form of sodium and glucose cotransport protein in glucose cotransport protein, blocks the reabsorption of glucose by the proximal convoluted tubules. Reduces glucose reabsorption by the kidneys and increases the excretion of glucose in the urine, thereby reducing plasma glucose levels. The hypoglycemic effect did not depend on the function of beta cells and was not affected by insulin resistance
Product Method of Bulk Empagliflozin Powder.
